Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.27
BCRX's Cash to Debt is ranked higher than
58% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. BCRX: 1.27 )
BCRX' s 10-Year Cash to Debt Range
Min: 1.19   Max: No Debt
Current: 1.27

Equity to Asset -0.02
BCRX's Equity to Asset is ranked lower than
51% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BCRX: -0.02 )
BCRX' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.97
Current: -0.02

-0.02
0.97
F-Score: 2
Z-Score: -6.28
M-Score: -4.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -177.24
BCRX's Operating margin (%) is ranked higher than
64% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. BCRX: -177.24 )
BCRX' s 10-Year Operating margin (%) Range
Min: -17879.61   Max: -18.42
Current: -177.24

-17879.61
-18.42
Net-margin (%) -173.72
BCRX's Net-margin (%) is ranked higher than
63% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. BCRX: -173.72 )
BCRX' s 10-Year Net-margin (%) Range
Min: -17170.39   Max: -18.03
Current: -173.72

-17170.39
-18.03
ROA (%) -61.61
BCRX's ROA (%) is ranked higher than
57% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. BCRX: -61.61 )
BCRX' s 10-Year ROA (%) Range
Min: -69.27   Max: -7.22
Current: -61.61

-69.27
-7.22
ROC (Joel Greenblatt) (%) -10038.24
BCRX's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. BCRX: -10038.24 )
BCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10038.24   Max: -35.66
Current: -10038.24

-10038.24
-35.66
Revenue Growth (%) -39.50
BCRX's Revenue Growth (%) is ranked higher than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. BCRX: -39.50 )
BCRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 430.1
Current: -39.5

0
430.1
EBITDA Growth (%) -14.10
BCRX's EBITDA Growth (%) is ranked higher than
71% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. BCRX: -14.10 )
BCRX' s 10-Year EBITDA Growth (%) Range
Min: -41.9   Max: 64.5
Current: -14.1

-41.9
64.5
EPS Growth (%) -10.20
BCRX's EPS Growth (%) is ranked higher than
76% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. BCRX: -10.20 )
BCRX' s 10-Year EPS Growth (%) Range
Min: -38.4   Max: 52.9
Current: -10.2

-38.4
52.9
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BCRX Guru Trades in

Q2 2012

BCRX Guru Trades in Q2 2012

Jim Simons 149,003 sh (New)
» More
Q3 2012

BCRX Guru Trades in Q3 2012

Jim Simons 70,129 sh (-52.93%)
» More
Q4 2012

BCRX Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BCRX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 26.60
BCRX's P/S is ranked lower than
68% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. BCRX: 26.60 )
BCRX' s 10-Year P/S Range
Min: 0.73   Max: 1000
Current: 26.6

0.73
1000
EV-to-EBIT 1.60
BCRX's EV-to-EBIT is ranked higher than
91% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. BCRX: 1.60 )
BCRX' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 1473.6
Current: 1.6

0.3
1473.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.60
BCRX's Price/Median PS Value is ranked lower than
73% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BCRX: 3.60 )
BCRX' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 38.53
Current: 3.6

0.13
38.53
Earnings Yield (Greenblatt) 61.20
BCRX's Earnings Yield (Greenblatt) is ranked higher than
87% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BCRX: 61.20 )
BCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 355.1
Current: 61.2

0.1
355.1
Forward Rate of Return (Yacktman) 16.14
BCRX's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. BCRX: 16.14 )
BCRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -54.7   Max: -27.4
Current: 16.14

-54.7
-27.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany
BioCryst Pharmaceuticals is a Delaware Corporation originally founded in 1986. The Company is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. Structure-guided drug design is a drug discovery approach by which it designs synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company has two Purine Nucleoside Phosphorylase (PNP ) inhibitors that are in development, ulodesine for the treatment of gout and forodesine for the treatment of hematological malignancies. PNP is a purine salvage pathway enzyme. Low doses of PNP inhibitors could be useful in reducing serum uric acid for the treatment of gout, while high doses of PNP inhibitors could be useful in the treatment of hematological malignancies. The FDA regulates the pharmaceutical and biotechnology industries in the U.S., and its drug candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide